Statyny vs inhibitory PSK9: zmniejszenie stężenia LDL-C a redukcja ryzyka sercowo-naczyniowego

Brian A. Ference i wsp. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart j 2018: 39, 2540–2545 (dostępny pełen tekst)1

In conclusion, the results of the FOURIER and SPIRE trials demonstrate that lowering LDL-C with a PCSK9 inhibitor reduces the risk of major cardiovascular events by the same amount as statins per mmol/L reduction in LDL-C. The magnitude of the observed risk reduction in the FOURIER and SPIRE trials was exactly what would have been expected based on the Cholesterol Treatment Trialists meta-analysis of statin trials …

14 lipca 2018